This decommissioned ERA site remains active temporarily to support our final migration steps to https://ualberta.scholaris.ca, ERA's new home. All new collections and items, including Spring 2025 theses, are at that site. For assistance, please contact erahelp@ualberta.ca.
Search
Skip to Search Results- 2phage therapy
- 1Aerosol phage therapy
- 1Burkholderia cenocepacia
- 1Burkholderia cepacia
- 1Burkholderia cepacia complex
- 1Depolymerase
-
Spring 2013
In recent times, increased attention has been given to evaluating the efficacy of phage therapy, especially in scenarios where the bacterial infectious agent of interest is highly antibiotic resistant. In this regard, phage therapy is especially applicable to infections caused by the Burkholderia...
-
Burkholderia cenocepacia requires complete lipopolysaccharide to resist bacterial killing agents
DownloadSpring 2023
Antibiotic-resistant infections are a growing concern, if this issue is not addressed by the year 2050 these infections will cause ~10 million deaths per year. Traditional antibiotics targeting essential life processes have demonstrated a rapid rate of resistance development. Modern antibiotics...
-
Fall 2022
Bacteriophages are highly abundant viruses that replicate within and effectively kill specific target bacterial hosts. The specificity of phages to their host relies on the presence of the correct cell surface receptor that is recognized by phage receptor binding proteins. These properties make...
-
Fall 2010
Plaques formed by DC1 on B. cepacia LMG 18821 and B. cenocepacia PC184 are surrounded by large and expanding halos when production of the exopolysaccharide (EPS) cepacian is induced. This plaque morphology indicates that DC1 putatively carries an EPS depolymerase enzyme. Plaque halos were absent...